Biosimilars offer affordable medical treatments, but regulatory guidelines need updating to ensure safety, efficacy, and ...

India needs to update its biosimilar regulations to ensure safe, effective, and affordable medicines, balancing quality and cost for better patient care.

With this partnership, they aim to enhance access to affordable treatments for patients suffering from autoimmune diseases ...

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, ...

China's Bio-Thera Solutions has entered into an exclusive commercialization agreement with India's Dr. Reddy's Laboratories ...

The Board of Directors of the African Development Bank (the "AfDB") has approved a EUR 15 million senior corporate loan to Minapharm Pharmaceuticals S.A.E. (Minapharm), a leading biopharmaceutical ...

We have the strongest in-house developed product pipeline in the biosimilar industry based on official available data. Ten products are in advanced development and additionally 18 molecules have ...

Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) today published its audited consolidated financial statements for the 2024 financial year and provided an outlook for fiscal year 2025 ...

Dr. Reddy's inks collaboration deal with Bio-Thera to develop and commercialize proposed biosimilar candidates of J&J's Stelara and Simponi in Southeast Asia.

This investment will support Minapharm' s expansion and renovation program, significantly boosting the development and production of affordable biosimilars for oncology and autoimmune diseases ...

Introduction Biosimilar monoclonal antibodies (mAbs) are biologic drugs designed to be highly similar to already approved reference monoclonal ...

I Gedeon Richter Plc. announces today that the European Medicines Agency has accepted Richter’s marketing authorization application (MAA) for ...